Mike Holland is one of the founders and Chief Executive Officer of Clinipeptide.com (Clinipeptide), a specialized provider of high-quality, research-grade peptides and therapeutic solutions. Under his leadership and close collaboration with the Clinipeptide team the company partners with clinical researchers, healthcare providers, and institutions focused on regenerative medicine, metabolic health, metabolic optimization, and anti-ageing protocols.

​

With more than three decades of experience at the intersection of health innovation, strategic operations, and enterprise growth, Holland works with the team to focus on delivering premium peptide products and solutions that accelerate scientific discovery and clinical outcomes while maintaining the highest standards of quality and compliance.

​

The Clinipeptide team’s work centers on bridging advanced biotechnology with practical clinical applications. Holland leads efforts to incorporate cutting-edge peptide synthesis, stringent process based guidelines and rigorous third-party testing into Clinipeptide’s operating model. This ensures researchers and clinicians receive peptides of exceptional potency, purity, and reliability, supporting breakthroughs in regenerative therapies, metabolic health, and longevity science. His approach emphasizes quality assurance, regulatory alignment, scalable production, and measurable value for research partners, enabling faster innovation and better patient outcomes.

​

A key focus of Holland’s work with the Clinipeptide team involves building strategic partnerships with research institutions, healthcare providers, and industry collaborators. He drives diligence on supply chain integrity, product innovation, and expansion into new therapeutic areas while overseeing post-development commercialization and integration strategies. Working with the Clinipeptide team he has helped position the company as a trusted source for tailored peptide solutions.

​

Founded under the Clinipeptide team and Holland’s vision, Clinipeptide.com has established a strong reputation for excellence in research-grade peptides and therapeutic applications. The company specializes in operating under stringent process-based guidelines, delivering consistent quality for clinical research, and providing customized solutions that meet the evolving needs of the regenerative medicine and wellness communities.

 

Holland received a Bachelor of Science in Marketing and a Master of Science in Accounting from the Martin J. Whitman School of Management at Syracuse University. Throughout his career, he has applied his strategic and operational expertise across health, wellness, and technology-enabled ventures to improve governance, strengthen performance, and deliver sustainable value through science-driven innovation and disciplined growth.